EMulate Therapeutics

A Disruptive Digital Therapeutics Company Leveraging Proprietary Radio Frequency Energy Platform Technology With Multiple Market Opportunities

Who We Are

EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®), to provide safe and effective therapeutic treatments for numerous unmet medical needs.

EMulate has to date established subsidiarity companies to bring its technology to people suffering from cancer, acute and chronic pain, and mental health conditions.

 

Cellsana Therapeutics

EMulate Therapeutics subsidiary, Oncology

Cellsana is pivotal (phase III) trial ready for treatment of Glioblastoma (GBM) and Diffuse Midline Glioma (DMG)

Cellsana has large market opportunities in a wide range of cancer indications.

Testing in humans and animals for safety and effectiveness in treating GBM and DMG has produced encouraging results.

Further, test results suggest our technology’s safety and effectiveness for treating solid cancer tumors such as mycosis fungoides, plasma cell tumors, fibrosarcomas, neurofibrosarcomas, schwanomas, malignant melanomas, hermangiopericytomas, hepatic adenocarcinomas, mast cell tumors, adenocarcinomas (mammary), osteosarcomas, chondrosarcomas, apocrine gland adenocarcinamoas, undifferentiated carinomas, and transitional cell carcinomas.

 

Mensana Therapeutics

EMulate Therapeutics subsidiary, Mental Health

Mensana is feasibility (phase I) trial ready for treatment of PTSD, depression, anxiety and addiction by the application of specific psychoactive ulRFE fields, another expression of EMulate’s Therapeutic technology.

Benefits of ulRFE treatment:

ulRFE fields are not controlled substances

Shorter duration of effect than actual psychoactive compounds

Patient can turn off the medical device if in distress; wears off quickly

MD prescribes, therapists can administer independently

Most psychedelic drugs have no composition of matter protection. The use of ulRFE fields is eligible for utility patent protections.


 

Indolor Therapeutics

EMulate Therapeutics subsidiary, Pain Management

Indolor Therapeutics is feasibility (phase I) trial ready for the treatment of acute and chronic pain by the application of specific pain-managing ulRFE fields, another expression of EMulate’s Therapeutic technology.

Preclinical testing for safety and effectiveness in humans and animals is complete.

Several different pain models were assessed.

Animal data show pain reduction greater than reference drugs in neuropathic pain model and noticeable activity in two other animal models.


 

Meet our team

  • Chris E. Rivera

    President, CEO & Chairman

  • Donna Morgan Murray, PhD

    Chief Regulatory Officer

  • Xavier Figueroa, PhD

    Vice President, Pre-clinical Development

  • Bennett M. Mike Butters

    Founder and Principal Inventor

  • Steven E. Pope

    Senior Vice President, General Counsel, and Corporate Secretary

  • Kyle J. Kingma

    Principal Financial and Accounting Officer
    General Manager - Subsidiaries

Learn more